With tech titans across the pond already leading the way, I’ve been thinking about which UK stock will smash it out of the park in the years ahead and be the first to pass the trillion-pound valuation.

For entertainment purposes only, I decided to put the question to ChatGPT.

The main contenders

Rather than just spit out the name of a single company, the bot actually provided me with a list of potential candidates. While far from being risk-free, the first four of these seemed reasonable enough.

BAE Systems has been winning contracts galore as a result of increased geopolitical tensions, the tragic wars in Eastern Europe and the Middle East and higher defence spending.

Market darling Rolls-Royce also made the cut. In addition to benefitting from the same earnings tailwinds, the engineer’s foray into SMRs (small modular reactors) could realistically send the share price even higher as we continue to transition to cleaner energy sources.

The snag is that both of these FTSE 100 stocks trade on high valuations. Will investors’ already-lofty expectations be met?

Oil giant Shell and banking behemoth HSBC were also put forward, mostly due to these already being among our biggest listed businesses and making huge profits. But both the oil and gas sector and financial services are cyclical. Earnings are dependent on a host of things they can’t control.

Perhaps with these concerns in mind, the bot called out AstraZeneca (LSE: AZN) as its top pick.

Why does AI love this UK stock?

ChatGPT believes the pharma stock is the one to watch because it’s “continually replacing its ageing products with new ones“, giving it an “enormous advantage” over the others.

I’m not sure I buy this as a reason for AstraZeneca to be the obvious winner. I’d say the nature of military conflict has changed markedly in recent years, forcing companies in this space to adapt and have huge growth potential so we can’t ignore BAE, for instance.

Still, we know populations around the world are ageing and that AstraZeneca is likely to benefit from this trend. The company possesses a large and diversified drugs pipeline. It’s this attribute that has attracted investors for a while, arguably at the expense of its main London-listed rival GSK.

Now, if AstraZeneca were able to ramp up the number of high-margin, blockbuster drugs it owns in the years ahead, it’s feasible that a trillion-pound valuation will arrive.

Risky business

Of course, AstraZeneca is hardly a safe bet either. Drug discovery has long been slow and difficult. Indeed, multiple disappointments at trials go some way to explaining why the stock has performed poorly in 2026, drastically lagging the FTSE 100 index as a whole.

Rumours in August of a potential merger with Bristol Myers Squibb also went down like a lead balloon with investors.

This only serves to underline my belief that betting the house on just one business is something I’d never consider doing, especially if the initial suggestion comes from an AI bot. There’s a very real possibility that none of the above become our first trillion-pound company.

Personally, I’d rather not speculate too much. Owning a diversified portfolio of quality UK stocks that grow my wealth over time remains the priority for me.

Should you invest £5,000 in AstraZeneca Plc right now?

When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca Plc made the list?

Paul Summers has no position in any of the shares mentioned.